Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCK1 | P35558 | 16/20 | 0.48 |
| ▸ | RORA | P35398 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613199 | 0.88 | PCK1 (0.47) | PCK1 | |
| SCHEMBL3978661 | 0.86 | PCK1 (0.53) | PCK1 | |
| SCHEMBL6280440 | 0.86 | PCK1 (0.47) | PCK1 | |
| SCHEMBL3977690 | 0.83 | PCK1 (0.52) | PCK1 | |
| SCHEMBL3982176 | 0.83 | PCK1 (0.50) | PCK1 | |
| SCHEMBL4614243 | 0.83 | PCK1 (0.53) | PCK1DPP4DPP7 | |
| SCHEMBL4615362 | 0.82 | PCK1 (0.60) | PCK1 | |
| SCHEMBL4615659 | 0.82 | PCK1 (0.59) | PCK1 | |
| SCHEMBL4615633 | 0.82 | PCK1 (0.59) | PCK1 | |
| SCHEMBL4612956 | 0.81 | PCK1 (0.55) | PCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | claimed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | claimed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | PCK1 36/4885RORA 289/4885RORC 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.